A

fter concerns mounted a decade ago over financial ties between drug makers and doctors, various institutions took steps to limit potentially undue influence over medical research and practice. The federal government created a website where companies are required to report payments. And many academic medical centers and physician practices barred or restricted visits by drug sales reps.

But to what extent have these efforts made a difference?

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.